Once harvested from the inner cell mass (ICM), embryonic stem cells (ESCs) undergo extended proliferation in culture as undifferentiated cells poised for multilineage differentiation. Confirmation of the pluripotent status of these cells involves both morphological criteria and specific molecular markers, and expression of typical marker genes. Nanog, a divergent homeodomain protein that directs propagation of undifferentiated cells, is down-regulated during early de-differentiation and becomes silent in completely differentiated cells. RNA from cloned and in vivo derived ESCs was extracted and qRT-PCR performed to assess their stemness. Molecular markers and morphological criteria were used to confirm ESC pluripotency. MII oocytes retrieved from B6D2-F1 mice were enucleated, injected with cumulus cell nuclei, and then activated using SrCl2. Blastocysts generated in vivo were similarly cultured and served as controls. Embryos were evaluated daily for their growth, hatching, and attachment to a feeder cell layer. After reaching an adequate size, ICMs were isolated mechanically 4 days later and trypsinized to provide single cells. RNA was isolated from ESCs derived from in vivo and cloned embryos, with mouse embryonic fibroblasts (MEF) serving as a negative control. qRT-PCR was performed with custom-designed primers for the target sequences of Nanog, Oct-4 (pluripotent markers), and Ttr genes, while Act-β and Gapdh were used as normalizers. Gene expression was reported as a proportion, calculated from the cycle threshold against Act-βconsidered at 100% expression. Quality and stemness were assessed according to morphological characteristics such as cell size, nucleus/cytoplasm ratio, and nucleolar patterns. In addition, pluripotency markers such as alkaline phosphatase activity, Oct-4 and TROMA-1 expression were also assessed. Of 17 oocytes that survived cloning, 12 constructs displayed two pronuclei, 4 developed further to produce fully expanded blastocysts, and 2 produced ESC lines of good quality. On the other hand, 40 (87.5%) in vivo-derived zygotes developed into blastocysts, and once plated 7 (20.0%) produced ESC lines. ESC colonies of both origin contained at least 60% of undifferentiated cells according to morphological characteristics and molecular markers. Between 10,000 and 30,000 cells processed generated 0.3 to 0.9 μg of total RNA that displayed two ribosomal subunits. Reverse transcription and qRT-PCR were successful in all specimens. As expected, Nanog was not expressed in MEFs whereas the in vivo and cloned-derived ESC cells revealed a similar 74.6% and 66.6% expression, respectively (χ2 = 1.19). Similarly, Oct-4 was not expressed in MEFs while the in vivo and cloned-derived ESC had an upregulation of 76.9% and 67.8%. MEFs manifested a higher expression (69.6%; P = 0.001) of Ttr (a marker of differentiation) compared to the in vivo and cloned-derived ESC colonies (40.7 and 49.2%, respectively). Results coming from a genomic indicator accord with those from other molecular markers in establishing stemness of the ESC colonies. Microarray analysis showed that clone-derived ESCs have similar expression patterns to those generated in vivo, and therefore that they may be used for stem cell therapy.
Read full abstract